frequency of bcr-abl fusion transcript in iranian patients with chronic myeloid leukemia

Authors

m yaghmaie hematology-oncology and bone marrow transplantation research center, shariati hospital,tehran, iran

s.h ghaffari hematology-oncology and bone marrow transplantation research center, shariati hospital,tehran, iran

k alimoghaddam hematology-oncology and bone marrow transplantation research center, shariati hospital,tehran, iran

a ghavamzadeh hematology-oncology and bone marrow transplantation research center, shariati hospital,tehran, iran

abstract

introduction: reverse transcriptase-polymerase chain reaction (rt-pcr) assay is a useful tool for the detection of fusion transcript resulting from specific chromosomal translocation of the leukemia cells. a specific chromosomal abnormality, the philadelphia chromosome (ph), is present in 90% to 95% of cml patients.the aberration results from a reciprocal translocation between chromosome 9 and 22, creating a bcr-abl fusion gene.there are two major forms of the bcr/abl fusion gene,  involving abl exon 2, but including different exons of bcr gene. the transcripts b2a2 or b3a2 code for a p210 protein. another fusion gene leads to the expression of an e1a2 transcript, which codes for a p190 pro-tein. another, less common fusion genes are b3a3 or b2a3 (p203) and e19a2 (p230). the incidence of one or other rearrangement in chronic myeloid leukemia (cml) patients varies in different reported se-ries. in general, fusion transcripts are determined individually, a process which is labor intensive in or-der to detect all major fusion transcripts. methods: this study was designed to determine the frequency of different fusion genes in 75 iranian patients with cml. peripheral blood samples were analyzed by multiplex reverse transcriptase poly-merase chain reaction (rt-pcr) from adult patients to detect all types of bcr-abl transcripts of the t (9:22) and found that all cases were positive for some type of bcr/abl rearrangement. results: most of our patients showed b3a2 fusion gene (62%), while the remaining showed one of the transcripts of b2a2, b3a3, b2a3, e1a2 or coexpression of b3a2 and b2a2. the rate of coexpression of the b3a2 and b2a2 was 5%. conclusion: in contrast to the other reports, we did not see any coexpression of p210/p190. this may reflect either the sensitivity of the detection techniques used or the possibility of genetic differences be-tween the populations studied. coexpression may be due to alternative splicing or to phenotypic varia-tion, with clinical course different from classical cml.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Frequency of BCR-ABL Fusion Transcripts in Iranian Azeri Turkish patients with Chronic Myeloid Leukemia

Background: The Philadelphia chromosome (Ph) characterized by t (9; 22) (q34; q11.2) is a reciprocal translocation giving rise to a chimeric BCR-ABL fusion gene. Incidence of Ph chromosome is over 98% in Patients with Chronic Myeloid Leukemia (CML) and around 20% in acute lymphoblastic leukemia (ALL). The finding of this fusion gene is essential for diagnosis of CML by detection of various fusi...

full text

BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran

Background: A specific chromosomal abnormality, the Philadelphia chromosome (BCR-ABL fusion), is present in all patients with chronic myeloid leukemia (CML). The b2a2 and b3a2 fusion mRNAs encode p210 fusion protein p210 and e1a2 encode p190. The aim of this study was to evaluate the frequency of BCR-ABL fusion transcript variants in Northeast of Iranian CML patients and to compare the laborato...

full text

Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.

BACKGROUND A specific chromosomal abnormality, the Philadelphia chromosome, is present in 90 - 95% of patients with chronic myeloid leukemia. The aberration results from a reciprocal translocation of chromosomes 9 and 22, creating a BCR-ABL fusion gene. There are two major forms of the BCR-ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcript b2a2 or b...

full text

Frequency of Bcr-Abl Fusion Oncogene Splice Variants Associated with Chronic Myeloid Leukemia (CML)

BCR-ABL fusion oncogene originates from the reciprocal translocation of chromosome 9 and 22 t(9;22) (q34;q11). It translates a chimeric protein, p210, characterized by constitutive activation of its tyrosine kinase, which triggers leukemogenic pathways resulting in onset of chronic myeloid leukemia (CML). In CML, the classic fusion is b2a2 or b3a2 fusing exon 13 (b2) or exon 14 (b3) of BCR to e...

full text

Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission

BACKGROUND The monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction (RT-qPCR) has become important to assess minimal residual disease (MRD) and standard of care in the treatment of chronic myeloid leukemia (CML). In this study, we performed a prospective, sequential analysis using RT-qPCR monitoring of BCR-ABL gene rearrangements in blood samples from 91 C...

full text

BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran

Background A specific chromosomal abnormality, the Philadelphia chromosome (BCR-ABL fusion), is present in all patients with chronic myeloid leukemia (CML). The b2a2 and b3a2 fusion mRNAs encode p210 fusion protein p210 and e1a2 encode p190. The aim of this study was to evaluate the frequency of BCR-ABL fusion transcript variants in Northeast of Iranian CML patients and to compare the laborator...

full text

My Resources

Save resource for easier access later


Journal title:
international journal of hematology-oncology and stem cell research

جلد ۲، شماره ۳، صفحات ۱-۵

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023